🔗 Share this article

While America undertakes unprecedented adjustments to its vaccination schedules, one figure has surfaced somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who first made her name by questioning coronavirus vaccinations in the pandemic and has focused upon possible deaths following Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Program

Health officials had intended to announce radical changes to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a major change that would place the US at odds with a large portion of the global community with no evidence for benefit. The announcement has been postponed until the next year.

Rather than Vinay Prasad, Høeg is scheduled to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

A Shift at the Regulatory Body

This interim role might represent a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing certain childhood shot schedules in the US to become more similar to Denmark, a nation with universal health coverage and a population about the population of the state of Wisconsin.

So far comments, she has kept her attention on vaccines – usually the responsibility of Prasad, chief of the FDA’s CBER – rather than medication approval.

Questions Over Background

The appointee has no obvious experience in medication creation, oversight or management, which has been typical for former heads of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who led CBER have had.”

The drug center has an enormous workload at the FDA, the former commissioner pointed out.

“Everybody just zeroes in on the novel medication approvals, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and every single one must be managed,” she explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major administrative aspect to the role, which manages in excess of 5,000 personnel. “It is a enormous management job, if you do it right,” Woodcock said.

Official Statement and Controversial Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment represents greater collaboration among FDA leaders on vaccines, a spokesperson stated that the “concerns stem from incorrect presumptions”.

“Her experience is consistent with the functions of her position,” the spokesperson stated, pointing to the period Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a controversial rapid drug-approval program that allegedly concerned her preceding directors. “By what process are these therapies being selected for this voucher program? Who makes the choices?” Dr. Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he stated, “the agency looks to be trending towards laxer rules of all drugs, with the exception of vaccines.”

Established Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if troubling, history, critics have noted. She published a analysis using unverified public submissions to assess the rate of myocarditis following Covid immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new administration featured changing rules for recently developed shots and ending “non-essential” vaccines, she said after the election on a podcast. At the agency, Dr. Høeg has allegedly proposed excluding young men from obtaining COVID-19 vaccines.

“She is an complete true believer who commences with her conclusions and tailors the evidence to fit the evidence in a very disingenuous, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow dissenters, {like|